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ABSTRACT
Development of a Robust Methodology to Obtain and Assess Myogenic Precursor Cells
for Their Use in Regenerative Therapies
Ricardo Lasa Rivas
Peripheral arterial occlusive disease (PAOD) is characterized by buildup of atherosclerotic plaque
in peripheral arteries that leads to an occlusion that can interrupt the supply of blood to the
peripheral tissue, causing downstream tissue ischemia/hypoxia. PAOD is estimated to affect over
200 million patients worldwide. Current surgical revascularization treatments can be effective in
about half of the patient population, leading to a significant number of patients with no treatment
options beyond pharmacological intervention and lifestyle modification. The decrease in blood
flow downstream of the occlusion leads to increased blood pressure gradient in the
microvasculature, specifically in vessels that connect arterial trees (known as collaterals), which
will structurally enlarge and increase blood flow to the downstream ischemic/hypoxic tissue.
Targeting this process, known as arteriogenesis, can provide a potential treatment option for
patients suffering from PAOD by redirecting blood flow around an occluded artery and therefore
supplying hypoxic tissue with blood. In order to enhance this process, cellular transplantation has
been used but the current cell types explored have not been successful in enhancing arteriogenesis.
Myoblasts, proliferative muscle progenitor cells, mediate muscle regeneration, and promote
angiogenesis (the growth of new capillaries to supply hypoxic tissue). Preliminary data indicates
that myoblasts also promote arteriogenesis in obese mice, making them an attractive therapeutic
candidate. However, the methods used in the preliminary studies limited our ability to confirm
those findings and characterize the cell therapy candidate. Specifically, we lacked a reproducible
and optimized method to isolate myogenic cells and characterize these cells during in vitro culture
and after in vivo transplantation. Therefore, the 1st Aim of this study was to optimize the isolation
to obtain the highest number possible of satellite cell-yielding myofibers by modification of
enzymatic and mechanical digestion of extensor digitorum longus muscle. Modifications to this
methodology increased myofiber yield by more than 150%. The 2nd Aim was to optimize the
expansion of satellite cell-derived myoblasts by modification of culture media supplements to
promote cell expansion while minimizing maturation. bFGF and SB 203580 supplementation
improved cell proliferation and prevented myogenic cell maturation during 7-days of in vitro
culture. The 3rd Aim was to develop a process for evaluating the quantity and identity of isolated
myogenic cells before and after transplantation. This was achieved by implementing an
immunofluorescent transcription factor labeling protocol to determine cell identity and a live/dead
cell viability assay to determine cell viability and quantity. All 3 aims were integrated into a proofof-concept pilot study on a hindlimb ischemic BALB/c mouse model. While myoblast
transplantation failed to increase collateral arteriogenesis in this model, the process developed in
this project provides a reproducible framework for future studies on myoblast-enhanced
arteriogenesis. Further research on the effects of myoblast transplantation on arteriogenesis may
facilitate the development of new therapies that improve the prognosis of patients with PAOD.
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1. INTRODUCTION
Peripheral Arterial Occlusive Disease (PAOD) is characterized by the buildup of atherosclerotic
plaques on arterial walls, primarily in lower extremities (Figure 1)1,2. This leads to a narrowing of
arteries and reduction in blood flow to the affected area, resulting in ischemia. PAOD is estimated
to affect over 200 million individuals
worldwide3. Patients develop pain in the
affected extremities that can lead to
functional impairment (intermittent
claudication), which is the most common
symptom of PAOD3,4. In more severe
cases, ischemia can also lead to gangrene
and subsequent amputation3–5.
Treatments for PAOD revolve around the
reduction of risk factors for
atherosclerosis, such as lifestyle
modifications or pharmacological

Figure 1: Peripheral Arterial Occlusive Disease.
Narrowing of artery due to plaque buildup reduces
blood flow supply to extremities.

management of blood pressure and clot formation (antiplatelet drugs can be administered to
patients to decrease the likelihood of clot formation but do not serve as a therapy for reducing
PAOD)1,3,6. Surgical revascularization procedures (such as bypass grafts) or more modern
endovascular revascularization strategies (angioplasty) are employed to improve blood flow once
the delivery of oxygen and nutrients reaches critically low levels (i.e Critical Limb Ischemia) and
have been successful in restoring blood flow to ischemic areas7,8. However, not all patients
qualify for either endovascular revascularization or surgical revascularization (often elderly
patients are not good candidates and can have adverse effects), leading to a patient population that
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does not benefit from any approach7,9. There is a clear need for new therapies to improve
outcomes for patients with PAOD.
One possible alternative would be to increase blood flow through the microvasculature around the
affected artery, effectively forming a natural bypass. Collateral vessels (also known as arteriole
anastomoses) connect arterial trees while also perfusing local muscles10,11. They can provide a
potential bypass around an occluded artery,
allowing blood from an upstream arterial
tree to flow into the occluded artery
downstream of the stenosis. The process by
which collateral vessels enlarge by
outward remodeling into larger
conductance vessels is known as
arteriogenesis, which provides a natural
process to return blood flow to the affected Figure 2: Arteriogenesis returns blood flow to
ischemic area. An occlusion in the main artery
tissue though the formation of a natural
causes loss of blood flow and development of
ischemic tissue downstream. The increase in blood
bypass (Figure 2)11–15. The increase in
flow across the collateral vessel triggers
arteriogenesis and enlarges, returning blood supply
shear stress due to the rise in pressure
to the ischemic tissue. Adapted from Chillo et al.,
2016 with the permission of Cell Reports13.
gradient across the collateral vessel
initiates the vascular remodeling process. This increased wall shear stress activates endothelial
cells (ECs), which release pro-arteriogenic factors and pro-inflammatory cytokines (such as
MCP-1, FGF-2, TGF-β, uPA, and MMPs), including chemokines that attract leukocytes12,14,16–19.
Activated ECs separate and increase vascular permeability, allowing for the migration of
leukocytes into the surrounding tissue17–19. Macrophages and monocytes adhere to ECs and later
extravasate into the perivascular space where they signal other cells to begin the remodeling
process17–19. Macrophages undergo polarization, a process by which they transition from a pro-
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inflammatory state (M1) to an anti-inflammatory state (M2)17,19. The initial M1 state helps attract
other leukocytes thorough the release of proinflammatory cytokines, while the M2 state releases
pro-arteriogenic cytokines19. These pro-arteriogenic cytokines promote paracrine signaling
between ECs and smooth muscle cells (SMCs) which coordinate the enlargement of the inner
endothelial layer and outer smooth muscle layer through their proliferation17–19. The result from
this cascade of events is an enlarged collateral blood vessel capable of increasing blood flow to
the ischemic area. However, the extent of collateral circulation (and subsequent collateral
enlargement) varies greatly among individuals due to genetic and environmental factors20,21.
Gene and protein-based therapies have the potential to mimic arteriogenesis due to their ability to
deliver growth factors to a specific area. Vascular endothelial growth factor (VEGF) is a primary
regulator of arteriogenesis as it promotes endothelial cell proliferation8,22. Many studies have
attempted to stimulate arteriogenesis by delivering recombinant human VEGF (rhVEGF) viral
vectors containing the VEGF gene8. While VEGF delivery promotes arteriogenesis in animal
models, it has had little success in human patients (only small clinical trials have been
successful)8. Gene-based therapies experience the added issue of correctly delivering the genetic
material to the target cells, which negatively impacts their success8. Other growth factors,
including combinations of several factors, have also been studied but have had similar success to
VEGF8. Arteriogenesis is a complex process that involves the expression and activity of many
different proteins; this complexity combined with potentially inaccurate doses may explain the
limited success of gene and protein-based therapies8,23.
Cell-based therapies offer a new alternative to gene and protein-based therapies due to their
ability to produce multiple growth factors in the correct physiological levels, mimicking the
natural process observed in vivo. Candidate cell types for regenerative therapies are selected
based on their regenerative role in the body. Cell therapies have also been developed around their
ability to secrete growth factors and promote physiological processes. The first cell types
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investigated to promote arteriogenesis were bone marrow-derived mononuclear cells (BMMNCs). BM-MNCs are a combination of multiple cells found in the bone marrow, and carry out
an extensive regenerative function in renovating multiple tissues such as blood vessels and neural
tissues due to their multipotent capacity24. In response to ischemia-induced cytokines released by
peripheral tissue, these cells are released into circulation and contribute to vascular remodeling.
This includes the secretion of matrix metalloproteinases (such as MMP-9) which regulate the
release of factors from the extracellular matrix (ECM) and secretion of further factors
downstream, as well as incorporating into the vessel wall and differentiating into SMCs and
ECs24–27. Studies using animal models found BM-MNCs enhanced arteriogenesis but these results
did not translate into clinical trials11,24. The next cell type used was bone marrow-derived
mesenchymal stem cells (BM-MSCs), originally identified in the vascular niche of peripheral
tissues, which help maintain human mesenchymal tissue (connective, vascular, and lymphatic
tissues)28–30. That these cells are routinely found adjacent to blood vessels and their role in
maintaining mesenchymal tissues makes them an ideal candidate to promote vascular remodeling.
Stem cells possess the ability to self-renew (formation of an identical daughter cell) and
differentiate into a specific cell types, allowing for their culture and expansion, which aids in the
development of the therapy31. Similar to BM-MNCs, BM-MSCs were successful in promoting
arteriogenesis in animal models but were unable to do so in clinical patients11. BM-MSCs can
differentiate into endothelial progenitor cells (EPCs)28,30. As their name suggests, EPCs, that can
circulate or reside in the blood vessel wall, mature into endothelial cells that line the inside of
blood vessels during vascular remodeling28,30. This ability has made this cell an attractive
candidate for vascular regeneration therapies. EPCs are effective in animal models but have yet to
demonstrate efficacy human clinical trials24,32,33. The progression of the different cell types for
this therapy, from bone marrow derived cells to more mature EPCs, shows a trend in the pursuit
of a specific cell type that regulates the vascular remodeling and the stem cell niche present
around blood vessels. Myogenic precursor cells have been identified as candidates in therapies
4

aimed at regenerating muscle, through their transplantation and fusion with the existing tissue,
but also regulate vascular remodeling34–38. Satellite cells (SCs) are part of the myogenic cell
lineage and exist in the vascular niche where they regulate vascular remodeling, making them an
ideal candidate for this therapy34–38. The primary function of satellite cells is to repair and
regenerate myofibers, the principal component of a tissue comprising 40% of an adult human
body by weight, and is composed of multinucleated syncytia surrounded by the basal lamina39–45.
SCs reside between the sarcolemma (myofiber plasma membrane) and basal lamina in a quiescent
state, mediating the regular injury-cycle due to skeletal muscle activity39,43–50. SCs regulate
microtrauma repair by repairing/regenerating myofibers following exercise, which is one of the
most effective treatments for PAOD39,51. SCs are also involved in enhancing microvascular
growth/remodeling, and manipulating macrophage recruitment and phenotype through signaling
within the local niche39,51. SCs are characterized by the expression of the transcription factor
Pax739,43–50, and upon activation due to injury will begin expressing MyoD, while proliferating
and maturing, with a small subset of cells undergoing self-renewal39,43–50. SCs undergo several
rounds of proliferation before committing to the myogenic lineage, becoming myoblasts, which
will mature into myocytes with the expression of myogenin39,43–50. At this point, myocytes will
exit the cell cycle and fuse to form myotubes that can repair injured myofibers or regenerate
ablated myofibers39,43–50. During muscle regeneration, new capillaries must grow to support the
increased metabolic activity thorough angiogenesis. Angiogenesis follows a similar cascade of
events as arteriogenesis with the main difference being the initial stimulus. During angiogenesis,
hypoxia in the repairing tissue causes myofiber secretion of angiogenic factors; during
arteriogenesis the stimulus is endothelial cell activation from the increased blood flow and
subsequently increased shear stress on their surface.
The use of these cells in clinical studies for similar processes make them an attractive candidate
for our proposed therapy and provide a potential fast-track to clinical testing. The effects of
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presumptive SCs and their progeny on arteriogenesis have been evaluated by our group, which
found that these cells enhanced collateral capillary arteriogenesis in BALB/C mice and collateral
arteriogenesis C57BL/6J mice with diet induced obese (DIO), but not in lean C57Bl/652–54.
However, the identity of the transplanted cells was not confirmed based on transcription factor
labeling, hence there is a need to verify the identity of these cells. The use of SCs for other
therapies can provide valuable information on their response to transplantation to determine their
constraints and advantages for this study. Specifically, clinical reports for various SC based
therapies, such as treating ischemia-damaged myocardium or Facioscapulohumeral Muscular
Dystrophy (FMS), can help us better understand the therapeutic potential of SCs and the logistics
behind their transplantation, and therefore facilitate the development of our proposed therapy34–38.
Use of these cells for myocardial repair depends on their ability to impact angiogenesis15,55. The
secretion of pro-angiogenic factors by SCs enhances the angiogenic process; the similarities
between angiogenesis and arteriogenesis provides a theoretical basis for the ability of SCs to
promote arteriogenesis17,35,55. FMS studies rely on the transplantation of SCs into a specific tissue
and ensuring they remain at the site of implantation, the methodology used for such studies
allows us to understand the potential limitations of our cell delivery strategy38. The proposed
approach aims to utilize the SC’s ability to signal cells in the blood vessel to activate and remodel
the vessel outward as opposed to muscle regeneration though SC transplantation, which would
rely on their ability to fuse with existing tissue and repair damage.
To better understand the therapeutic potential of SCs for promoting arteriogenesis, we must first
optimize the approach to isolate them. Myofiber isolations work by separating individual
myofibers from a muscle body and culturing them to promote SC migration off the fiber onto the
culture flask. Myofiber isolations can produce high purity myoblast cultures and do not require
extensive purification steps such as fluorescent cell sorting (FACS) and cell preplating56,57. The
most critical step in myofiber isolations is the enzymatical digestion of the muscle. During this
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process, the excised muscle is placed in a solution containing an enzyme (e.g. collagenase II),
capable of digesting connective tissue and allowing for easier separation of individual myofibers.
This process involves careful regulation of enzymatical activity to ensure the muscle is
sufficiently digested to yield large numbers of myofibers while avoiding over digestion and loss
of myofiber viability. Other steps, such as mechanical separation of myofibers, also affect the
overall yield and must be optimized along with enzymatic digestion to ensure enough SCs have
been isolated for subsequent studies.
Once SCs have been isolated from whole muscle, they are expanded in tissue culture flasks to
obtain a suitable amount for transplantation or in vitro characterization. Their expansion can be
optimized by the addition of factors that enhance their proliferation and inhibit their
differentiation. SC proliferation and differentiation is regulated by signaling from other cells
found in the muscle stem cell niche47,49. Two major pathways identified and studied in SC culture
are the basic fibroblastic growth factor (bFGF) pathway, which regulates proliferation and
differentiation, and the p38 MAPK pathway, which plays a key role primarily in SC
differentiation. Within the p38 MAPK pathway, a stress-activated protein kinase 2a/b
(SAPK2a/b) also known as P38α/β, reversibly enhances SC quiescence by insulating the cell
from external stimuli58,59. bFGF has been widely used in studies involving primary SC culture and
has a dual role of stimulating myoblast proliferation and repressing terminal differentiation57,60–66.
bFGF stimulates cyclin D1, a regulatory subunit of the cyclin-dependent kinases (CDK), which
are expressed during the growth-1 (G1) phase of the cell cycle62–65. Cyclin D1 regulates the
transition from G1 to S-phase of the cell cycle and therefore stimulates proliferation64. Cyclin D1
expression also inhibits myoblast differentiation64. Pharmacological inhibition of P38α/β
promotes SC self-renewal and allows expansion of SC ex vivo with enhanced self-renewal in
human SCs, while reducing terminal differentiation67. In both single myofiber cultures and shortterm SC cultures of cell lines (MM14), SB 203580, which is a p38 mitogen-activated protein
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kinase (MAPK) inhibitor that targets P38α/β, allows SCs to maintain their quiescent state. P38α/β
MAPKs are required primarily for differentiation but are also involved in proliferation58,59,67–69.
Interestingly, satellite cells and MM14 cells supplemented with SB 203580 failed to respond to
changes in bFGF70. The combination of bFGF and p38 inhibition is part of our current protocol
and has demonstrated a combination of their benefits during the cell expansion phase, but their
roles are commonly regarded as being antagonistic to one another52–54,70,71. Initial SC isolations
did not include bFGF or SB 203580 supplementation53. bFGF was added to improve cell
expansion, but with the increase in cell number, SCs began to mature at a faster pace and so SB
203580 was added to reduce the rate at which these cells matured and maintain a myogenic
progenitor cell population54,71. From observational data, the combination of both supplements has
the potential to optimize current expansion protocols by slowing down maturation while
maintaining an actively dividing myoblast population, but we must empirically validate these
observations through studies looking at the effects of each supplement separately and combined
in varying concentrations.
High yielding SC isolations are not only required for their transplantation, it is also critical to
characterize them in vitro. Using fluorescent antibody labeling of transcription factors can help us
identify the phenotype of the cells in culture. As described above, Pax7 and MyoD can help us
determine if the cells in culture are myogenic progenitor cells47. If Pax7 and MyoD are not
present, the cell population has matured into myocytes or myotubes47. These strategies can be
adapted to assess cell phenotype on the transplantation vehicle. Assessment of cell distribution on
the vehicle can help us understand potential limitations in their delivery. These strategies can be
simple, such as performing live/dead staining to evaluate cell viability during different stages of
the study, to extremely complex, such as the use of superparamagnetic iron oxide nanoparticles
(SPIO) to tag transplanted cells for noninvasive visualization using MRI72. Regardless of the
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methodology implemented, understanding both cell phenotype and distribution would allow us to
assess the cellular component of the proposed therapy.
In summary, our preliminary data demonstrates that transplantation of presumptive myoblasts can
promote arteriogenesis52–54. Confirming those preliminary results will require identification of
transplanted cell phenotype, distribution, and viability, along with measurement of cell transplant
efficacy in an animal model. To confirm these results, we must first obtain sufficient cells
through their expansion. Cell expansion is impacted by the effectiveness of initial cell isolation
and subsequent culture media optimization. Optimizing this process will require empirical
determination of culture conditions which maximize in vitro expansion. Once we are able to
expand our cell cultures to yield sufficient cells, we must develop a strategy for their
transplantation. Transplant efficacy depends on several factors, including the vehicle used and the
distribution and retention of the cells during the study. All these considerations will be
summarized into the three main aims of this thesis:
•

The first aim is to optimize the myofiber isolation and culture to obtain the highest
number possible of satellite cell-yielding myofibers and support the initial SC culture.
o

Objective: To optimize myofiber isolation and SC culture conditions by
modification of the enzymatic and mechanical digestion of the extensor
digitorum longus muscle and modifying media formulation.

•

The second aim is to optimize the expansion of satellite cells-derived myoblasts to
promote cell expansion while minimizing differentiation.
o

Objective: To optimize culture media by modifying the dosage of bFGF and p38i
supplementation to promote maximum cell proliferation and minimal cell
maturation.

9

•

The third aim will be to develop a process for evaluating the quantity and identity of
isolated myogenic cells before and after transplantation and implementing all of these
aims into an in vivo pilot study.
o

Objective: To implement an immunofluorescent transcription factor labeling
protocol to determine cell phenotype.

o

Hypothesis: Myoblasts will secrete the necessary growth factors to promote
arteriogenesis, leading to an increase in collateral expansion. Myocytes are too
mature of a cell type to secrete the necessary growth factors for vascular
remodeling and therefore not lead to an increase in collateral expansion.
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2. METHODS
2.1 Animal Care
Male C57BL/6 and male BALB/c mice (Jackson Labs; Sacramento, CA) between 1 and 3 months
were housed 4 to 6 mice per cage with ad libitum access to water and food (14% protein rodent
maintenance diet, Envigo; Hayward, CA) in a temperature controlled facility with a 12:12 hour
light:dark cycle. All procedures were completed according to protocols approved by the
California Polytechnic University Institutional Animal Care and Use Committee.
2.2 Myofiber Isolation
Satellite cells (SCs) were obtained from single myofibers, which were isolated by enzymatic and
mechanical digestion, as previously described54. Animals were anesthetized in an induction
chamber with 5% isofluorane gas and euthanized by cervical dislocation. Animals were then
disinfected with 70% isopropanol. Skin was removed from the knee to the ankle and the
connective tissue around the Tibialis Anterior (TA) was blunt dissected on both hindlimbs. The
distal tendon of the TA was cut, and the muscle was carefully resected to expose the underlying
Extensor Digitorum Longus (EDL). The EDL was excised by cutting both distal and proximal
tendons to ensure myofiber integrity. The contralateral EDL was excised closely after to avoid
uneven digestion times. EDLs were immediately placed in a freshly prepared collagenase II
solution (2mg·mL-1 type 2 collagenase [Worthington LS004176] in HAMS F10 [Lonza 12-618F])
and placed in a water bath at 37⁰C to digest the connective tissue/matrix. Over approximately 25
minutes, the solution was occasionally inverted, and muscles were inspected every 5 minutes.
Once individual fibers appeared to start separating from muscle body, the whole muscle was
transferred to a horse serum (HS, Fisher 16050122) coated 100mm petri dish (Fisher
FB0875713), and filled with 20mL of wash media (20% fetal bovine serum [FBS, Fisher 10-437028], 1% penicillin/streptomycin [Fisher SV30010] in Hams F-10 media), with a custom glass
pipet coated with HS. Muscles were mechanically digested by gentle trituration using wash
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media. Once enough live myofibers were isolated (~75 myofibers per T12.5 flask), they were
transferred to an identical petri dish to consolidate all viable myofibers. The viable myofibers
were finally transferred into a T12.5 (12.5cm3) flask (Fisher FB012933) or 24-well plate
previously coated overnight with ECM (Sigma E1270-1ML) and supplemented with 10ng·mL-1
bFGF (PeproTech 100-18B-100UG) and 10µM SB 203580 (p38 inhibitor, Fisher 120210) prior
to incubation at 37⁰C and 5% CO2. ECM is a protein solution which provides a thin coating layer
promoting cell adhesion to the surface of the culture flask, it mainly consists of extracellular
matrix proteins laminin and collagen IV.
2.3 Myoblast Culture
Once myofibers are isolated from the excised muscles, they are cultured in tissue flasks so SCs
can migrate off them and can then be expanded during culture. Initial myofiber culture was left
undisturbed for 3 days and imaged using an inverted microscope (Olympus CKX41). Satellite
cells began to migrate off the myofibers onto the flask after one to three days in culture. On day
5, a partial media exchange was performed by transferring existing media into an equal volume of
fresh growth media (wash media supplemented with 10ng·mL-1 bFGF and 10µM p38 inhibitor),
lightly mixing, and transferring half of the mixture back into the flask (collecting suspended
myofibers during pipetting). This approach ensures that nutrients are replenished while retaining
in culture suspended myofibers that did not adhere to the flask, but are still viable and can release
additional SCs onto the flask. Once local colony confluency reached ~80%, cells were rinsed with
DPBS (Fisher 14-190-144) and released using a gentle dissociation buffer containing EDTA
(Fisher- Gibco 13151014), leaving highly adherent cells in the flask (~1% of total cells). Released
cells in media were centrifuged at 300 x g for 5 minutes, the supernatant aspirated, and
precipitated cell pellet resuspended in warm, fresh growth media and counted using a manual
hemocytometer counter (INCYTO DHC-N01-5). To continue expansion, cells were seeded on a
T25 flask (25cm3, Fisher 10-126-10), which was coated overnight in ECM. To immunostain, cells
12

were plated for 12 hours and fixed on 8-well chamber slides (Fisher 12-565-8). Alternatively,
cells were also resuspended after centrifugation in 80% FBS (Fisher SH3091003) and 20%
DMSO (SIGMA D2650) for cryopreservation. To determine optimal supplement dosage,
individual fibers were cultured separately in a 24-well plate (Fisher 3526) for 3 days. For the in
vivo study, separate myoblast and myocyte populations were prepared to ensure the appropriate
cell type was transplanted for each group. The myocyte group was prepared using the same
culture techniques previously described but removing the p38i from the culture media during
complete culture to promote cell maturation.
2.4 Immunofluorescence
Cell phenotype was explored based on myogenic transcription factor expression using
immunofluorescent labeling. Cells were fixed in 4% paraformaldehyde (PFA, Fisher 50-980-487)
at room temperature for 10 minutes, rinsed with DPBS, and then permeabilized in 0.5% Triton X100 (VWR M236-10ML-5PK) in DPBS for 5 minutes. Blocking solution (UltraCruz Blocking
reagent, Santa Cruz Biotech sc-516214) was added for 30 minutes before incubating fluorescently
labeled primary antibodies in blocking solution (1:200, Pax7 and MyoD from Novus Bio NBP234706AF594 and NB10056511F, respectively) for 60 minutes at room temperature. Primary
antibodies were conjugated with Alexa 594 and FITC, respectively. Coverslips were sealed with
DAPI-containing mounting medium (Santa Cruz Biotech sc-359850) prior to image capture with
an Olympus BX41 widefield fluorescent microscope and QCapture pro. Images were captured at
10X and 20X magnification and analyzed using Image/J.
2.5 Gelatin Hydrogel Preparation
To deliver the cells to the target area, a gelatin hydrogel vehicle was prepared. After boiling to
dissolve, a 10% (w/v) gelatin (Sigma G1890-100G) solution was dispensed into wells of a 24
well plate and left to polymerize for 30 minutes. The polymerized hydrogel was then incubated in
sterile 6mM 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC, Fisher
13

PIPG82079) to crosslink the gelatin overnight at 4⁰C. Gelatin was washed with sterile H2O 3x for
30 minutes prior to cell seeding at a density of 2.5x105 cells·cm-2; seeded gelatin was incubated at
37⁰C for 12 hours.
2.6 Femoral Artery Ligation and Transplantation
Animals were initially anesthetized in an induction chamber with 5% isofluorane in oxygen. Once
anesthetized, isofluorane was maintained at 1-3% and a flow rate of 0.5-1.5 min-1. Animals were
weighed and provided analgesic (buprenorphine at 0.075 mg/kg). The surgical area was depilated
and then disinfected with chlorohexidine diacetate (Nolvasan). Animal internal temperature was
maintained by a heat pad placed under the surgical stage controlled by a rectal thermistor.
Ophthalmic ointment was applied to prevent corneal desiccation. An initial incision was made
parallel to the femoral artery directly near the epigastric fat pad, and connective tissue was blunt
dissected. Once the neurovascular bundle was exposed, the femoral artery was carefully isolated.
Using 7-0 silk suture, the femoral artery was ligated distal to the epigastric and proximal to the
popliteal arteries. Gelatin hydrogels were prepared using a 2mm biopsy punch and placed in a
‘pocket’ that was prepared by undermining the gracilis muscles. The incision was then closed
using 7-0 prolene suture. Post-operative analgesia was delivered every 24 hours for 3 days. The
same procedure was performed on the contralateral hindlimb with the exception of artery
separation, femoral artery ligation, and gelatin hydrogel transplantation. This procedure was
performed with the assistance of Ada Tadeo and Jaden Frazier.
2.7 Functional Vasodilation
To assess the effects of myoblast transplantation on arteriogenesis, functional vasodilation was
performed to explore changes in collateral outer diameter and function. The construct was also
retrieved to explore the effects of transplantation on the cells. Seven days post transplantation,
animals were anesthetized and prepared as described above. A skin incision was made directly
above the anterior gracilis to expose it, and the gelatin hydrogel was removed and placed in PBS
14

for evaluation. To stimulate muscle contraction, tungsten microelectrodes (FHC- PBSA1075)
were placed on the surface of the gracilis, midway between the saphenous and profunda arteries;
an intravital microscope (Olympus BXFM) was positioned above the collateral midzone and the
exposed area was covered with plastic wrap. After a 30-minute equilibration period, the muscle
was stimulated for 90 seconds at 8Hz with 1mA stimuli of 200µs duration; images were captured
immediately following the cessation of muscle contraction. Sodium nitroprusside (1x10-4) and
norepinephrine (1x10-4) were dripped over the muscle to maximally dilate and constrict the
collateral vessel, respectively. This procedure was repeated for the contralateral hindlimb. This
procedure was performed by Ada Tadeo.
2.8 Vascular Casting
To explore changes in collateral inner diameter and vessel wall thickness, vascular casting was
performed. After the functional vasodilation assessment, animals were prepared for vascular
casting using Microfil [Flow Tech Inc. MV-120]. Through a left ventricular cannula, vasodilator
cocktail (400 µL Heparin, 25 mM Sodium Nitroprusside, and 1.5 mM Adenosine in 38mL of
PBS) was perfused at a rate of 5 mL·min-1 to clear the circulation of blood and fixation solution
(4% paraformaldehyde in PBS) was perfused at a rate of 4 mL/min to preserve the tissue. Once
the femoral artery had been cleared of blood and fixed, the Microfil was perfused via the same
left ventricular cannula at 0.5 mL·min-1. Once the vascular cast was complete, the animal carcass
was stored at 4°C overnight. The gracilis muscle was then excised and placed in a
microcentrifuge tube containing 2% Triton X-100 in PBS for 2 hours at room temperature to
permeabilize the muscle. The muscle was then incubated in a 1:400 Anti-Alpha Smooth Muscle
Actin antibody [Sigma Aldrich C6198] solution in a 2% Bovine Serum Albumin (BSA) [Sigma
Aldrich A2153] and PBS solution for 96 hours at 4°C in the dark. The muscle was washed with
0.1% Triton X-100 in PBS 3x for 10 minutes and then in PBS for 30 minutes prior to slide
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mounting in a solution of 50:50 PBS:Glycerol [Sigma Aldrich G7757]. This procedure was
performed by Jaden Frazier.
2.9 Image Analysis
Vessel diameters and cell counts were performed with ImageJ software using the line measuring
tool and multipoint tool, respectively. Vessel diameter was measured 5 times to determine
average diameter and 3 independent cell counts were performed for each sample to determine
average cell count.
2.10 Statistical Analysis
Statistical analysis was performed using Minitab statistical software. Differences in cell counts
and transcription factor expression for changes in media supplementation, as well as differences
in resting and dilated vessel diameters and collateral wall thickness between treatment groups
were determined using one-way ANOVA and compared via Tukey post-hoc comparisons. A
p-value of less than 0.05 indicated statistical significance. Values are presented as mean values
with standard error (mean ± SE).
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3. RESULTS
Developing a myogenic cell therapy to enhance arteriogenesis, aimed at patients suffering from
PAOD, requires a robust methodology which allows us to assess the different components
separately and then combined during a pilot study. From our preliminary data, we found that
presumptive myoblasts can enhance arteriogenesis52–54. Hence, our goal is to replicate that study
after including a more extensive assessment of the cell therapy candidate to overcome the
limitations from previous studies, including the lack of cell characterization both during culture
and after transplantation. This refined methodology includes an optimization of the initial
isolation and culture of the target cell type, their characterization based on specific transcription
factors during different stages of their culture, as well as on the transplantation vehicle pre- and
post-transplantation, culminating in a final pilot study combining all previous studies with an
evaluation of the impact of myogenic cell transplantation on arteriogenesis.
Satellite Cell Morphology
To determine the different morphological stages of myogenic cells under the culture conditions
used in this study, images of the cultures were captured at different stages and stained for Pax7
and MyoD transcription factors to confirm their phenotype (Figure 3). Four main stages of SC
morphology were observed during culture. Initially, presumptive SCs on the surface of myofibers
appeared round upon transfer of myofibers onto culture dish (Figure 3A). As they migrated off
the myofiber and adhered to the surface of the culture flask they began to elongate and adopt a
triangular shape from day 1 to day 8 (Figure 3A, B). Myogenic cells that remained in culture for
extended periods of time (more than 10 days) and formed confluent presumptive myocyte
populations (~80%) that appeared to commit to a final maturation by elongating and orienting
themselves in arcing patterns (Figure 3C). These presumptive myocyte populations would then
to fuse and form large multinucleated myotubes (Figure 3D), which were initially (around 20
days after isolation) surrounded by myocytes and did not exhibit spontaneous contraction. As the
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remaining myocyte population fused together, myotubes began to mature and were capable of
spontaneous contraction (Figure 3E). Samples from early cultures in which SCs had recently
migrated off myofibers were positive for Pax7 and MyoD, confirming their identity as early
myogenic progenitors (Figure 3F, G, H, I). Samples of cultures at stages in which cells began to
elongate and orient themselves stained negative for Pax7 and MyoD, confirming they were no
longer myogenic progenitor cells (Figure 3J, K, L). Using these results and the distinct
morphological changes observed during myogenic cell culture, we were able to estimate
phenotype based on a morphological assessment of the cells. These estimations allowed us to
quickly evaluate myogenic cultures by visual observation during the culture and expansion stages
of cells for transplantation. Now that we were able to determine the identity of the cells in culture,
we began optimizing their isolation.
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Figure 3: Progression of primary isolated myogenic cells during in vitro culture. A, presumptive satellite
cells recently migrated from a myofiber (Scale bar 100µm). B, presumptive myoblasts expanding during
culture (Scale bar 100µm). C, presumptive myocytes beginning to align in dense formations (Scale bar
100µm). D, Early multinucleate myotubes surrounded by myocytes (Scale bar 200µm). E, Mature
myotubes capable of spontaneous contraction (Scale bar 20µm). F, G, H, I, Immunofluorescent labeling
of MyoD (G) and Pax7 (H) in 100% of nuclei (F) confirmed myoblast phenotype in population/similar
population as (B), MyoD, Pax7, and DAPI merged image (I) (Scale bar 20µm). J, K, L, Absence of
immunofluorescent labeling of MyoD (K) and Pax7 (L) in 100% of nuclei (J) confirmed myocyte
phenotype in population/similar population as (C) (Scale bar 20µm).

19

Myofiber Isolation Optimization
To perform multiple studies on the behavior of SCs in vitro and perform a pilot study to
determine their impact on arteriogenesis, a robust method to maximize cell yield was required to
obtain sufficient cells. To develop more efficient cell isolation procedures, a number of isolations
were performed under different conditions and evaluated using cell number at various stages in
the culture. Figure 4 displays cell number from each passage of 6 select isolations in
chronological order (Figure S1 in Appendix C contains additional images of the myofiber
isolation process). Table 1 summarizes the changes made between isolations and the results
observed after they were implemented. We can broadly group these changes into 3 categories:
mechanical and enzymatical digestion methods, and media supplementation. Initial changes in
enzymatical digestion methods included changing from frozen to freshly prepared collagenase II
solutions. The effects from this change were immediately observed, as the time required for
enzymatical digestion decreased from ~45 minutes to ~20 minutes, but the more critical effect
was the improved separation of myofibers from the entirety of the muscle body, even deep inside
the muscle. While frozen collagenase II solution would release myofibers on the surface of the
muscle, the fresh solution separated fibers deeper inside the muscle and allowed for faster and
higher yielding myofiber isolations (Table 1, Isolation 3). Mechanical digestion improvements
came from improving the connection between the micropipette and the custom glass tip to ensure
an airtight seal. This allowed for greater control over media flushing and myofiber collection,
leading to a greater number of myofibers isolated and reducing shear stress during transfer, which
could result in myofiber death (Table 1, Isolation 2). After changing bFGF and p38i dosages, SC
migration from myofibers and expansion of myogenic cells in culture improved. Increasing
supplements of bFGF increased SC number, while greater inhibition of p38 MAPK reduced
myogenic cell maturation. Finally, improvements in technique included smoother and more
controlled flushing of media, which may have reduced the stress on the myofibers and increased
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the amount of viable myofibers isolated, as well as transferring only viable myofibers into the
final petri dishes to avoid introducing dead myofibers into the culture flask. These improvements
were a result of performing multiple isolations, implementing these techniques, and observing
how they affected myofiber isolation and viability. All the changes during this objective lead to
the initial optimization of isolating myofibers from muscle increasing day-10 yield by nearly an
order of magnitude, from 3x105 to 1x106 cells. Having made most gross changes to the isolation
protocol, the next step was to empirically optimize the effect of media supplementation on initial
SC migration from myofibers.

Table 1: Myofiber Isolation Optimization Results Summary
Isolation
Changes (based on previous isolation)

Result

bFGF Dose: 2 ng/mL
1

Cell counts: 3x105 (Day 10)

p38i Dose: 5 µM
Frozen Collagenase II solution

2

Improved pipette connector

Higher number of myofibers
isolated (+50%)
Cell counts: 7x105 (Day 10)
Higher number of myofibers
isolated (+100%)

3

Fresh Collagenase II solution

Cell counts: 3x105 (Day 8),
4x105 (Day 10), 6x105 (Day 18)
Myoblasts began to mature into
myocytes

4

bFGF Dose: 10 ng/mL

Cell counts: 7x105 (Day 7),
1.2x106 (Day 10), 4.25x106 (Day 17)
Lower myoblast maturation

5

p38i Dose:10 µM

6

Refined myofiber isolation technique

Cell counts: 6x105 (Day 7),
9x105 (Day 9), 1x106 (Day 12)
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Cell counts: 4x105 (Day 3),
1.1x106 (Day 7)

Figure 4: Cell number counts for select isolations. Evolution of cell number evaluated upon
passage during isolation protocol optimization starting from isolation 1 to isolation 6.

Supplement dosage response for initial myogenic cell migration and early expansion
Once we were able to efficiently isolate myofibers from muscle, we optimized bFGF and p38i
supplementation to ensure optimal migration and initial expansion of SCs from myofibers. To
maximize SC migration and initial expansion, media formulation was optimized by modifying
bFGF and p38i concentration. We explored the impact of varying concentrations of bFGF and
p38i on individual myofibers by applying different concentrations of bFGF and p38i in separate
wells of a 24 well plate (Figure 5). P38 inhibitor dose was varied (0X, 0.5X, 1X or 10µM, 2X)
while keeping bFGF dosage constant (1X or 10ng/mL) and vice versa; a control culture
containing no p38 inhibitor and no bFGF was also included). Myogenic cells that migrated off the
fibers were counted on days 1 and 3, and the fold increase for each treatment group was
calculated to compare the increase in cell number with the supplement concentration. bFGF
increased the number of cells migrating and expanding in the first 3 days of culture in a dosedependent manner (Figure 5C). SC count increased until the 1X dose (5.97 ± 0.50), at which
point the effect of bFGF supplementation plateaued, as no further increase was detected when its
concentration was doubled (6.83 ± 0.65). Supplementation using the 0.5X dose (4.17 ± 0.35) had
22

no effect on cell counts when compared to the 0X and No supplementation groups (3.36 ± 0.36
and 3.56 ± 0.29 respectively). Inhibiting p38 MAPK had no impact on cell number (Figure 5D)
at the 0.5X and 1X doses, (5.40 ± 0.31, and 5.97 ± 0.50 respectively), but reduced proliferation at
the 2X dose (3.56 ± 0.29). Surprisingly, the 2X dose lowered proliferation to the level of the no
supplement groups. The highest p38i dose that would not impact cell expansion and would reduce
myoblast maturation was determined to be the 1X dose. Optimal supplement concentration, with
regards to cell expansion, was 1X bFGF and 1X p38i. These supplement concentrations were
implemented to optimize cell expansion and maintain cell phenotype during migration from
myofibers and initial culture.

Figure 5: Initial myogenic cell migration and expansion in response to changes in bFGF and p38
inhibitor supplementation. A, Satellite cell migration after 1 day in culture (Black arrow: Satellite
cell, scale bar 200µm). B, Satellite cell migration after 3 days in culture (Black arrow: Satellite
cell, scale bar 200µm). C, Fold increase in myogenic cell number between culture day 1 and 3 in
response to changes in bFGF supplementation (*, p<0.05 vs 0.5X, 0X, and No supplements, &,
p<0.05 vs, 0X, and No supplements). D, Fold increase in satellite cell number between culture
day 1 and 3 in response to changes in p38 inhibitor supplementation (+, p<0.05 vs 1X, 0.5X, and
0X). n=3 wells for each supplement combination)
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Effects of supplements on SC expansion and differentiation
Myoblasts kept in culture for extended periods of time (past 72 hours) begin to mature at a faster
rate and start to lose proliferative ability. To maximize cell expansion and minimize maturation of
myoblasts, cultures were supplemented with bFGF and p38i, either factor, or neither factor.
Myogenic cells were cultured for 7 days, before assessing morphology, cell number, and
phenotype (Figure 6). Cultures were passaged before reaching more than 80% local confluency
to avoid effects of increased cell density on phenotype, as overly confluent cultures were
observed to promote myoblast maturation. Only the culture supplemented with both p38i and
bFGF reached confluency and was passaged on day 5. bFGF increased cell number compared to
the no-supplement control (8.6 ± 0.03 [x105] vs 0.43 ± 0.02 [x105]). The p38 inhibitor did not
increase cell number (0.53 ± 0.02 [x106]), but also did not affect bFGF-enhanced proliferation
(0.96 ± 0.04 [x106]) (Figure 6E). The impact of bFGF and p38i on differentiation was assessed
by phenotyping the cultures using MyoD and Pax7 as markers of early myogenic progenitor cells.
bFGF had no effect on MyoD expression, bFGF alone did not increase MyoD expression (92.9 ±
4.3%) when compared to other treatments (no supplements 81.1 ± 4.5%; p38i only 99.2 ± 0.8%),
but also did not affect the enhancement of MyoD expression by p38i (100 ± 0%, Figure 6F).
P38i alone however, increased MyoD expression as compared to the non-supplemented group.
There was no difference between p38i supplemented groups and bFGF only supplemented groups
(Figure 6F). Pax7 expression was not affected by bFGF or p38i but follows similar trends as
MyoD expression (Figure 6G). This evaluation of the effect of the bFGF and p38i
supplementation on 7-day expansion and phenotype suggest that bFGF supplementation supports
myoblast expansion but not MyoD and Pax7 expression. Conversely, p38i supplementation does
not increase myoblast expansion but does increase MyoD expression and seemed to have a
positive trend with respect to Pax7 expression. Maintaining MyoD and Pax7 expression is
desirable to maintain an early myogenic cell population which is highly proliferative. Due to the
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high adherence of mature cell types (mentioned in the myoblast culture methods), the results
shown in Figure 6 represent the maximum percentages of Pax7 and MyoD expression since
mature cell types which do not express either factor remained in the culture flask during
passaging. This results in smaller differences between treatment groups and does not fully reflect
the effects of the p38i supplementation. The actual differences between groups are likely to be
larger than the one illustrated below. The combination of both supplements seems to have the
highest potential as the optimal media formulation for cell expansion post migration and
maintaining the population at an early myogenic cell phenotype.

Figure 6: Effects of bFGF and P38 inhibitor supplementation on 7-day satellite cell culture. A, B,
C, D, Immunofluorescent labeling of MyoD (B) and Pax7 (C) in nuclei (A) at day-7 following
myofiber isolation; merged image (D) (Scale bar 20µm). E, Effects of bFGF and P38 inhibitor
supplementation on day 7 myoblast cell number (*, p<0.05 vs -/- and -/+), MyoD expression (F)
(*, p<0.05 vs -/-), and Pax7 expression (G) in day 7 myoblasts. One separate isolation per
treatment was performed and repeated 3 times (n=3).

25

Evaluation of the gelatin hydrogel vehicle
After optimizing the isolation and culture of SCs and developing a methodology to characterize
them, we prepared them for transplantation. For this process we adapted our characterization
methodology to visualize cell phenotype on gelatin and determine cell viability. To assess the
viability of the gelatin hydrogel vehicle for cell delivery, cell viability and cell phenotype were
evaluated pre- and post-transplantation (Figure 7). Cells were plated on the gelatin hydrogel
construct 12 hours pre-transplantation. To determine cell viability on the hydrogel and ensure live
cells were transplanted, a live/dead stain was performed prior to transplanting. Cell viability was
close to 99% (n=3) at 12 hours after plating for both myoblast and myocyte groups, with most of
the dead cells suspended in media instead of adhered to the hydrogel (Figure 7A). After the 7day transplantation study, the constructs were retrieved from the implant site for evaluation of
viability and myoblast phenotype. Cell viability 7 days post transplantation was <1% (n=3) for
the myoblast and myocyte groups (Figure 7C, D). No groups expressed MyoD or Pax7 (Figure
7J, K, L). Interestingly, the gelatin vehicle contained live and dead cells adhered on the construct
(Figure 7E, F). Implementation of the live/dead stain and adaptation of the characterization
methods were initially hindered by the inability to perform the necessary washing step during
immunofluorescent staining due to the construct’s physical properties, which made quantification
challenging. This was resolved by modifying the image acquisition parameters to filter out low
fluorescent signals. After evaluation of cell phenotype on the gelatin hydrogel pre- and posttransplantation, we determined that this vehicle allows us to transplant live cells after a 12-hour
plating period. From the post-transplantation results, we can observe that cell viability at day 7 is
absent and MyoD and Pax7 expression is also low.
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Figure 7: Evaluation of myoblasts on gelatin hydrogel. Live (A) dead (B) (white arrow)
myoblasts on gelatin 12 hours post-plating (Scale bar 100µm). Live (C) dead (D) myoblastconstruct on gelatin 7 days post-transplantation (Scale bar 200µm). Live (E) dead (F) cells of
gelatin vehicle 7 days post-transplantation (Scale bar 200µm, magnified image of dead stain on
bottom left corner, scale bar 100µm). Immunofluorescent labeling of MyoD (H) and Pax7 (I) in
myoblast nuclei (G) 12 hours post-plating on gelatin (Scale bar 20µm). Immunofluorescent
labeling of MyoD (K) and Pax7 (L) in nuclei (J) of myoblast-constructs 7 days posttransplantation (Scale bar 20µm) (Magnified image of DAPI stain on bottom left corner, scale
bar 100µm).
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In vivo evaluation of myoblasts and myocytes on collateral function and structure
To determine if myoblast or myocyte transplantation enhances collateral size and maturity, cells
were plated and transplanted (Figure 8) deep to the gracilis muscle during femoral artery ligation
in BALB/C mice. At 7-days following surgery, gracilis collaterals were imaged using intravital
microscopy to measure collateral diameter (Figure 9A, B). Myoblast and myocyte groups had no
effect on maximum collateral diameter when compared to the vehicle only group (Figure 9C).
From these results, we cannot conclude that myogenic cell transplantation enhanced collateral
expansion. Other possible effects, such as acceleration of collateral maturation could have
occurred. This was determined by assessing vascular tone and resting diameter, which was not
impact by the cell transplantation. These were measurements of internal diameter and did not take
into account the collateral wall thickness; myogenic cell transplantation may have increased
vascular smooth muscle proliferation and therefore collateral wall thickness. Therefore, collateral
wall thickness was assessed by subtracting the luminal diameter, determined from a vascular cast,
from the outer diameter, determined by an α-smooth muscle actin stain (Figure 10A, B). No
difference in collateral wall thickness was found between treatment groups (Figure 10C). These
results suggest that myoblast or myocyte transplantation did not promote collateral enlargement,
vascular wall growth, or maturation.
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Figure 8: Myogenic cells transplanted for in vivo evaluation. A, Myoblasts isolated from BALB/c
donor mouse pre-transplantation (Scale bar 100µm). B, Myocytes isolated from BALB/c donor
mouse pre-transplantation (Scale bar 100µm). C, D, E, F, Immunofluorescent labeling of MyoD
(D) and Pax7 (E) on myoblasts pre-transplantation compared to a DAPI nuclear stain (C) and
merged (F) in a single image (Scale bar 20µm).
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Figure 9: Collateral mean diameter measurements before and after electrical stimulation.
Intravital collateral image after myoblast transplantation before (A) and after (B) electrical
stimulation (Scale bar 50µm). C, Functional vasodilation and collateral diameter comparison
between treatment groups (Myoblast group n=3, Myocyte and gelatin groups n=4, Sham group
n=11, *, p<0.05 vs Gelatin, Myoblast, Myocyte, &, p<0.05 vs Sham Rest). Data collected and
analyzed by Ada Tadeo.
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Figure 10: Collateral vessel wall mean thickness measurements. A, Collateral vessel outer
diameter stained using α-smooth muscle actin after myoblast transplantation (Scale bar 100µm).
B, Collateral vessel filled with microfil after myoblast transplantation (Scale bar 100µm). C,
Collateral wall thickness compared between treatment groups for sham and operated hindlimbs
(No significant differences observed). Data collected and analyzed by Jaden Frazier.
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4. DISCUSSION
Peripheral arterial occlusive disease (PAOD) is characterized by the development of
atherosclerotic plaques in the larger peripheral arteries, which decreases blood perfusion to
peripheral tissues and causes ischemia1. With the limited selection of potential treatments and
their reported low efficacy, cell therapies have been proposed as alternate therapy candidate to
promote collateral arteriogenesis and provide a natural bypass to return blood perfusion to the
affected tissues7,9. Myogenic progenitor cells play an important role in muscle regeneration and
secrete a wide range of growth factors involved in macrophage recruitment and arteriogenesis41,43.
The potential of altering the local niche to promote collateral arteriogenesis makes these cells an
attractive candidate for treating PAOD. Early preliminary studies evaluating the impact of
presumptive myoblast transplantation on arteriogenesis found that these cells can enhance
arteriogenesis52–54. However, after failure to enhance arteriogenesis in later preliminary studies,
the focus of this study was to address the limitations related to myoblast isolation and
characterization. The first aim of the study was to update the myoblast isolation and culture
methodology and develop a reliable and effective approach to obtain sufficient cells of the
required phenotype to perform further studies. The second aim this study addressed was
confirming the identity of the cells transplanted using specific transcription factors, as well as
characterizing and assessing the viability of cells on the vehicle before and after transplantation.
A pilot study, similar to previous preliminary studies, was performed to synthesize all the aims of
the study and implement these newly developed methods to determine the effect of myoblast
transplantation on collateral arteriogenesis, while evaluating the cellular component of the
therapy during the study.
Initial Cell Phenotype and Morphology Assessment
Previous approaches to characterize myogenic cells by our group involved morphological
assessment of isolated cells to determine their phenotype71. To reliably use such a strategy, we
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must first confirm the identity of cell type using more robust methods to correlate/extrapolate the
morphology of these cells at different stages in the myogenic lineage. The first step of this
characterization process was to confirm that the isolated cells were indeed satellite cells (SCs)
and their progeny. To confirm this, we kept the isolated cells in culture and grew them until they
matured into myotubes, confirming their myogenic identity. Having confirmed the myogenic
potential and apparent absence of contaminating cell types, we assessed SC morphology during
all stages of myogenic cell culture and confirmed these observations with transcription factor
identification. Confirming the phenotype using transcription factor labeling and comparing these
to the morphology of the cells allows us to quickly infer myogenic cell phenotype based on visual
observation. This allows the individual culturing these cells to quickly assess the myogenic state
of the culture by inspecting the culture flask during passaging or feeding procedures. It was
determined that myogenic cells displayed four distinct stages during culture. They initially
presented as small round perturbations on the surface of myofibers and remained like this upon
initial migration onto the surface of the culture flask, at which point they would elongate and
appear triangular in shape. Myogenic cells would then initiate their commitment to terminal
differentiation and maturation, starting to elongate and orient themselves before finally fusing
together and forming myotubes. These stages were confirmed by the expression of Pax7 and
MyoD transcription factors during the earlier stages of culture, when cells were immature
myoblasts, and the absence of these transcription factors in later stages, when cells elongated and
became myocytes and myotubes. Pax7 and MyoD are expressed by early myogenic progenitor
cells, i.e. myoblasts; the expression of these factors diminishes once myogenic cells mature into
myocytes and myotubes39,43–50. It is worth noting that myogenic cell morphology is dependent on
the substrate they are cultured on. This is of importance if we want to infer cell phenotype based
on morphology. Different coating solutions and different materials affect morphology, therefore it
is important that these stages be identified at different institutions, and even within the same
group, as they might differ from the ones presented here. Performing this initial analysis allowed
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us to confirm our myogenic cultures were comparable to those of other groups47,60,70. Defining
these morphological stages and comparing them with myogenic factor expression allowed us to
quicky estimate cell phenotype based on morphological appearance and make efficient decisions
about their culture, such as passaging cells if some have started to mature. Further exploration of
the correlation between cell morphology and phenotype would involve finding a suitable
measurement methodology for cell morphology and identifying how transcription factor
expression correlates to those measurements. During transcription factor labeling, the use of
control stains was employed to ensure the correct identification of the cells and avoid any
bleedthrough effects from the different fluorophores. While the initial control stains were
successful in confirming the results from our staining procedures, future studies would benefit
from best practices during these assessments and include a control stain for every replicate to
ensure the validity of the results. (Figure S2 in Appendix C contains images of the control stains
performed). Phenotyping using these procedures presented further challenges when cells were
cultured on gelatin due to the inability to completely wash off the staining solution, which lead to
noise during imaging and made quantification challenging.
Isolation Optimization
The first step of the optimization process involved improving the isolation of individual
myofibers from Extensor Digitorum Longus (EDL) muscles. Changes to the initial protocol were
gradually implemented and evaluated both qualitatively, through morphological assessment of
cells, and quantitatively using cell number over time to determine the effectiveness of the isolated
myofibers with respect to cell expansion. The biggest improvement in increasing the number of
myofibers isolated came from using fresh collagenase II solution, which increased the amount of
myofibers isolated by more than 100% when compared to frozen aliquots of collagenase II.
The mechanical separation and handling of myofibers was also critical for their viability;
myofibers that were damaged during the transfer from the digesting flask to the culture flask
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failed to yield SCs and reduced the effectiveness of the isolation protocol. Damaged and dead
myofibers hypercontracted and failed to release SCs; in addition they also seemed to adversely
affect the myofibers around them, potentially due to the release of apoptotic cytokines73. Gentle,
consistent flushes of media were the best way to mechanically separate myofibers while
maintaining their integrity, which required micropipettes to aspirate and eject consistent volumes
of media. Periodic checks on the silicone adaptor seal used to connect the micropipette body to
the glass tips ensured that the mechanical digestion and transport of myofibers was consistent
between isolations. Regular maintenance of isolation equipment is critical to the success of the
isolation procedure.
Changes in supplementation, from a 2ng/mL to a 10ng/mL dose of bFGF, and from a
5µM to 10µM dose of P38 inhibitor, increased the number of cells and decreased maturation,
decreasing the time required for isolations to yield large numbers of proliferative myoblasts. The
concentrations of these supplements were further evaluated to ensure the optimal concentrations
were used.
Although the yield of myogenic cells was sufficient for in vitro studies and
transplantation into preclinical mouse models, this isolation method presents potential problems
for its translation into larger animal models and human use. The main drawback is the need for
whole, undamaged myofibers to be isolated for SCs to migrate off the fibers and onto the flask.
Even if we disregard potential rejection issues with transplanting donor cells, obtaining whole
muscles and then isolating myofibers seems unlikely and would be increasingly complex as the
size of the animal increases. To solve these potential issues, a bulk isolation method could be
implemented. In general, bulk isolations can be more efficient at obtaining larger numbers of
myoblasts than individual myofiber isolations, as the process of mechanically separating
individual myofibers can be time consuming and result in lower yields when compared to bulk
isolations56,57. However, individual myofiber isolations can produce higher purity myoblast
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cultures, in theory, since the only cell type that would be able to migrate off the myofiber would
be SCs56. The bulk isolation method involves mechanical and enzymatic digestion of minced
muscle fragments to liberate single cells from the myofiber parenchyma and requires several preplating steps to remove unwanted cell types based on differences between adhesion times and
adhesion strength57. This method quickly yields large numbers of myoblasts, making it ideal for
obtaining a sufficient number of cells for transplantation without requiring whole muscles, and
can be sourced from the recipient, circumventing rejection issues34,56,57,74. However, given the
target population for this potential therapy, patients could present with preexisting conditions that
impact the muscle and vascular tissue, which could present new problems, such as a diseased SC
population that is unable to be expanded to sufficient quantities41,51,56,66,75. With regards to
rejection, advances in biomaterials capable of avoiding an inflammatory response when
transplanted could protect allogeneic SCs. Future studies could replace single myofiber isolation
with bulk isolation and optimize this method to provide the same amount of undifferentiated
myogenic cells as the myofiber isolation method. Diseased mouse models (suffering from PAOD
or other diseases that this potential treatment could address) should also be explored to determine
whether the cells isolated from this patient demographic have lower proliferative capacity and
reduced potency41,51,56,66,75.
In summary, the isolation method was optimized by modifying the enzymatic and
mechanical digestion methods of the donor muscle, resulting in an isolation procedure capable of
producing highly pure SC cultures. The subsequent aim involved exploring the effects of
culturing myogenic cells in vitro and optimizing media supplementation to ensure the high purity
of the isolated cells was not lost while maximizing their expansion.
Effects of Supplementation on Short and Long Term Culture
To determine the optimal media supplementation to maximize SC activation and myoblast
expansion, we explored the effects of the supplements used during culture and their impact on
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cell expansion and phenotype. The addition of bFGF and inhibiting p38 MAPK seemed to
increase the number of immature myogenic cells.
To precisely determine their effect on myoblast proliferation and maturation, and SC
migration from myofiber cultures, we measured the increase in cell number in response to
different concentrations of bFGF and p38i. Cell expansion increased as bFGF concentration
increased. Interestingly, no further increases in proliferation were observed when the bFGF
concentration was doubled (10ng·mL-1 to 20ng·mL-1) (5.97 ± 0.50 to 6.83 ± 0.65). Inhibiting p38
MAPK had the opposite effect on cell expansion, decreasing cell expansion (5.97 ± 0.50 to 3.44 ±
0.29) when the standard dose was doubled (10µM to 20µM). These results seem align with those
presented by other groups, which found that inhibition of p38 MAPK decreased cell expansion
and did not recover with bFGF suplementation59,64,70.
Although these results support the choice of supplement concentrations used in this
study, there is still opportunity for further optimization. Specifically, the short culture time (72
hours) could explain why some groups are not significantly different. To test this hypothesis,
multiple isolations would have to be performed, each one supplemented with different
combinations of bFGF and p38i, and cultured for varying lengths of time. During the initial
isolation optimization, cultures resulting from low numbers of myofibers (fewer than 50 per
T12.5) stopped expanding and eventually began to die before reaching day 7, hence individual
isolations would be needed to provide enough myofibers (more than 75) for long term expansion.
We determined that three days was, on average, the longest a myofiber would ‘release’ SCs. This
was determined from observations during culture, where myofibers would detach from the
surface of the culture flask.
In summary, this study allowed us to determine that using a bFGF concentration of
10ng·mL-1 and a 10µM concentration of SB 203580 maximized SC migration and initial
expansion. To reach the required number of myogenic cells for transplantation, cells had to be
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cultured for about 7 days, hence the effects of these supplements were evaluated for this longer
time frame.
The role of bFGF and p38i on short term cultures (72 to 96 hours) has been previously
investigated, however, little work has been caried out to evaluate the combination of both
supplements in longer cultures (7+ days), specifically ones aimed at using them for the
development of a cell therapy58,59,68. The latter consideration is critical since extended exposure to
supplements could lead to unwanted effects on SC population (such as cell senescence) that could
impact their secretion of growth factors, affecting the therapy’s effectiveness59. Hence, the effect
of each supplement separately, and the combination of both, was evaluated based on cell number
and phenotype after 7 days in culture, as compared to a culture without any supplements. bFGF
supplemented cultures had higher cell counts than those without; inhibiting p38 MAPK did not
affect cell number. Cultures in which p38 MAPK was inhibited displayed higher MyoD
expression than cultures without supplements; no other conditions affected MyoD expression.
Neither supplementing bFGF nor inhibiting p38 MAPK affected Pax7 expression. The effect of
bFGF on myoblast proliferation is consistent with previous findings60,63. bFGF also represses
maturation of SCs by stimulating cyclin D1, which could explain why there was no difference
between groups supplemented with bFGF and with inhibited p38 MAPK in both MyoD and Pax7
expression61,63. SCs cultured with this specific p38 inhibitor (SB 203580) failed to expand with
changes in bFGF, preventing bFGF stimulated proliferation through the MAPK pathway70. If SB
203580 blocks bFGF induced cell proliferation, all groups supplemented with SB 203580 would
have similar cell number counts to non-supplemented cultures and would have lower cell counts
than bFGF only supplemented cultures. We observed cultures supplemented with both bFGF and
SB 203580 had similar cell counts to cultures supplemented with just bFGF, suggesting bFGF
was key in promoting cell proliferation and that p38i supplementation did not block its effect.
Studies show p38 MAPK inhibition has no effect on bFGF induced increases in cyclin D1
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through ERK signaling68,81. However, while bFGF signals through the ERK and p38 MAPK
pathways, ERK activation alone is not sufficient for myoblast proliferation68,81. A possible
explanation of these results would be that SB 203580 activity is time dependent. If SB 203580 no
longer inhibited the P38 MAPK pathway after a certain time point, potentially due to a decrease
in pharmacological activity (as it is used up, a behavior previously observed for other cell culture
media supplements), bFGF could activate this pathway, increase cell expansion, and explain the
results observed76. These previous studies mostly evaluate SC culture between 24 and 72 hours,
which could explain why they observed no cell expansion with increases in bFGF following p38i
supplementation (since p38i would still be active)64,70. However, it is worth mentioning these
groups used higher concentrations (20µM in primary isolated SCs) than the ones used in this
study and therefore further studies looking at the relationship between bFGF signaling and p38
MAPK inhibition could help clarify these results. A future study could look at the effects of these
supplements more accurately by evaluating SB 203580 activity with time, specifically looking at
inhibiting p38 MAPK at different stages of the culture (24 to 72 hours with no inhibition).
Mature cell types (those exhibiting no Pax7 or MyoD expression) are highly adherent and
remain on the tissue culture flask during passaging. This property is beneficial to purify our
cultures before transplantation and the dissociated cells are assessed and transplanted without
further culture or passaging steps, hence our results are representative of the cells transplanted.
However, this does affect the results (Figure 6), decreasing the number of non Pax7 or MyoD
expressing cells and results in smaller differences between treatment groups. This does not fully
reflect the effects of the p38i supplementation since the actual differences between groups are
likely to be larger than the one illustrated in Figure 6. The importance of the p38i
supplementation can be observed during the culture of myocytes where myoblast cultures quickly
mature into myocytes without p38i supplementation (Figure 5B).
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In summary, we validated the choice of media supplementation for extended cultures
(more than 72 hours) which allowed us to obtain large numbers proliferating myoblasts. Once we
had developed a robust method to obtain high yielding, high purity myoblast cultures, we began
to assess the delivery vehicle selected. This included characterizing cells on the vehicle as well as
determining their viability both pre- and post-transplantation.
Evaluation of the Gelatin Hydrogel Vehicle
Cell delivery strategies have been a highly researched subject in recent years as low retention
rates limit the effectiveness of cell therapies, there is a <10% survival rate after 48h following
direct injection of myoblasts into muscle77–79. Retention rate of cells refers to a quantitative
assessment of the number of transplanted cells which remain in the target area over time.
Different strategies include direct administration of cells in a buffer solution through injections
and delivery using a vehicle such as a hydrogel carrier80,81. Strategies for cell delivery must be
chosen with the proposed mode of action of the therapy in mind. For instance, a SC based therapy
that aims to regenerate muscle tissue through cell engraftment would need a vehicle which allows
for cells to fuse with native tissue. In the case of our therapy, strategies which maximize exposure
(high retention rates) of the target area to the paracrine factors produced by SCs would be
beneficial. Delivery strategies such as plating cells on injectable microscale cellular niches to
transplant these into ischemic mouse models have been developed, reporting superior retention
rates when compared to direct injection (96% on microscale niche versus 15% for direct
injection) and leading to a significant improvement in blood perfusion79,80,82. Delivery using a
vehicle such as a hydrogel carrier can result in higher retention rates than direct injection and are
more easily fabricated when compared to complex delivery systems such as microscale cellular
niches80,81. These studies demonstrate that delivery strategies are critical to a cell therapy’s
effectiveness.
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To transplant viable cells in a reproducible manner, a gelatin hydrogel vehicle was used
for its reproducibility and predictability. To evaluate the status of the cells on the vehicle, cell
retention and phenotype were estimated through cell viability staining and Pax7 and MyoD
transcription factor staining pre-transplantation and 7 days post-transplantation. Cell viability was
99% 12 hours after cell plating (pre-transplantation), but this number decreased dramatically to
<1% at 7 days post-transplantation. Myoblasts were Pax7 and MyoD positive pre-transplantation
(myocytes were negative for both) but there was no Pax7 or MyoD expression for any group at 7
days post-transplantation. Cell distribution after plating was inconsistent, with more cells
adhering towards the center of the well. This led to inconsistent treatment dosages since the
number of cells transplanted depended on the location where the transplant vehicle was punched
out of the well. In the case that a hydrogel punch was removed from an area with fewer cells, it is
possible that the effect of the cells in vivo would be diminished. The hydrogel was also difficult
to transplant under the anterior gracilis in a limited space, often leading to friction on the surface
of the hydrogel and possibly cells being removed from it. The drop in viability could be explained
by the lack of nutrients reaching the cells on the construct and the potential friction on cells due to
hindlimb movement. Cells in culture begin to differentiate soon after the cessation of bFGF
supplementation and inhibition of p38 MAPK, so it is possible that the lack of Pax7 and MyoD
expression could be due to myoblasts maturing. Myogenin staining could be used to identify
mature myocytes to test this hypothesis. Interestingly, nuclear staining revealed cells present on
the gelatin only vehicle, but live/dead staining revealed the same viability as with the other
groups. A possible explanation could be an inflammatory response by the host, although gelatin
displays a low inflammatory response, macrophages and other immune cells are attracted to the
foreign body and generally attempt to encapsulate it83–86. This process can lead to potentially
detrimental interactions between the host immune system and the transplanted cells, macrophages
could encircle the construct or other immune cells could release cytotoxic cytokines, which could
explain the low viability of cells 7 days post-transplantation and the presence of cells on the
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gelatin-only vehicle. Although a gelatin hydrogel is effective in delivering cells to the target area,
its effectiveness in maintaining their viability is not clear. The development of other vehicles,
such as injectable thermorevesible polymers, can improve the delivery of cells by improving the
ease of transplantation (removing the potential friction during implantation), increasing the
number of cells transplanted (since they are not limited to the surface of the vehicle), and
reducing foreign body response83–86. However, since cells will be embedded in the vehicle there
could be an impact on oxygen supply to the cells and secreted growth factors could be trapped
inside the vehicle.
We confirmed our ability to transplant viable myoblasts using the gelatin hydrogel
vehicle and gained a better understanding on the behavior of these cells on the vehicle. The final
stage of this thesis was to implement all of the previous aims into a pilot study similar to previous
studies performed by our group.
Effects of Myoblast Transplantation on Collateral Arteriogenesis
Myoblasts and myocytes on gelatin hydrogel disks were transplanted under the gracilis muscle of
BALB/c mice following femoral artery ligation. Neither myoblast nor myocyte transplantation
enhanced collateral arteriogenesis. This result is similar to prior studies, which found no increases
or inconsistent increases in collateral diameter after myoblast transplantation in lean C57Bl/6
mice87. However, myoblast transplantation did enhance collateral arteriogenesis in C57Bl/6 mice
with DIO and collateral capillary arteriogenesis in the spinotrapezius muscle of BALB/c mice52–
54,88

. Additionally, neither myoblast nor myocyte transplantation affected collateral wall

thickness. In addition to the limitations expressed above about potential issues with the gelatin
hydrogel vehicle, the site of transplantation and mouse strain used could also explain this
difference. Previous studies explored the effects of myoblast transplantation in DIO C57Bl/6
under the gracilis muscle and in BALB/c mice under the spinotrapezius muscle, where collaterals
form from capillaries undergoing arteriogenesis, forming arterialized capillary collaterals
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(ACC)52,54. Studies looking at the impact of myoblast transplantation on arteriogenesis in DIO
C57Bl/6 mice under the spinotrapezius muscle could show differences between implantation
sites. Studies performed in DIO C57Bl/6 mice found an increase in collateral diameter after
myoblast transplantation under the anterior gracilis88. This suggests that myoblast transplantation
in BALB/c mice is not as effective in increasing collateral arteriogenesis compared to the same
procedure in DIO C57Bl/6 mice. C57Bl/6 mice have extensive preexisting collateral circuits and
are capable of robust collateral development, which is a contrast to BALB/c mice which have
significantly fewer collateral circuits and display reduced collateral development and
enlargement89,90. Even if DIO C57Bl/6 mice also display an impaired arteriogenic response (due
to suppression of collateral growth), the difference in preexisting collateral circuits might explain
the difference in experimental results between strains91. Although our group previously found
myoblast transplantation promoted arteriogenesis in DIO C57Bl/6 mice but no impact in lean
C57Bl/6 during this study, these differences could be explained by a reduced exposure of growth
factors from transplanted myoblasts due to the low retention rate (evident from the low cell
viability after transplantation during this study). The work done for this thesis could be used to
determine whether these differences are due to differences in the transplanted cells. Further
studies on the arteriogenic response of each mouse strain could aid in the selection of a suitable
mouse model for future arteriogenesis studies.
Limitations
Technical limitations for the studies described herein that have not previously been described are
related to study design. The time required for the isolation and culture of myoblasts, and the
surgical procedures, lead to small replicate sizes (between n=2 and n=4 for the pilot study). This
impacted the randomization of the study, which was limited to cell availability. A larger supply of
animals for myogenic cell isolation and transplantation studies can help increase the number of
replicates in these experiments, reducing some of the variability present.
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Another important limitation lies in the complexity of immunofluorescent imaging, especially
with regards to imaging on gelatin. Gelatin is autofluorescent, which made imaging cells on the
gelatin hydrogels challenging by introducing noise in the form of bright light in the images taken.
Another potential source of uncertainty during imaging was the material characteristics,
specifically post-transplantation where the gelatin was in a more liquid state. During staining
procedures, the lowered viscosity of the gelatin made it challenging to perform the necessary
washing steps without aspirating the gelatin and could have trapped some of the
immunofluorescent molecules, resulting in extremely bright fluorescent images. These issues
resulted in potentially lower cell counts since some of the individual cells couldn’t be discerned
from the gelatin. The development of alternate transplantation vehicles mentioned above could
help overcome these limitations and allow for more accurate cell counts on the vehicle.
Conclusion
Regardless of the outcome of the pilot study, the strategy implemented during this project
provides a repeatable and complete framework to isolate, expand, and characterize myogenic
cells to assess the cellular component of the proposed cell therapy. From our results, we propose
the following framework to allow for more defined studies and easier comparison between
studies. The development of a cell therapy in the proof-of-concept stage in small animal models
involves four stages, cell isolation/sourcing, cell culture and expansion, vehicle development, and
in vivo evaluation. At the end of each stage there must be a critical evaluation of the process and
results obtained. After cell isolation/sourcing, the number of cells and their purity must be
analyzed to determine if the selected method for obtaining cells matches the expectations for
future steps. Once cells are obtained, we must evaluate the culture conditions and how these
ensure optimal cell expansion to achieve the desired number of cells of the appropriate
phenotype. This stage would involve determining proper media formulation to allow cells to
expand to sufficiently large quantities while maintaining the desired phenotype. This step is a
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critical addition to the previous procedure as it allows us to have more control over the in vitro
expansion of these cells. After assessing the culture conditions, reliable cell transplantation
strategies should be explored. Vehicle development is a critical stage that links the in vitro studies
performed so far and the implementation of the therapy in vivo. Key evaluations during this stage
involve interactions between the vehicle, cells, and animal subject. Here, we determined cell
viability on the vehicle and cell survival through early in vivo studies before determining the
effect of the therapy on collateral arteriogenesis. Material biocompatibility must also be assessed
when implementing a new vehicle, including inflammatory response and cytotoxicity. Finally, the
effects of the therapy in vivo can be evaluated. This stage involves the selection of a suitable
animal model, both biological and surgical, and well-defined endpoints that best evaluate the
desired clinical outcome. In the case of collateral arteriogenesis, a suitable mouse strain (which
has preexisting collaterals) and ligation site should be considered first, followed by assessment of
vascular response (through collateral enlargement, maturation, or innervation). Developing a
reliable and wholistic process can help researchers determine potential bottlenecks in the
development of the therapeutic candidate, and allow for appropriate resource allocation, which
has become increasingly important as cellular therapy developments become increasingly
expensive92,93.
In summary, we developed a reliable procedure to isolate, expand, and characterize
myogenic cells both during culture and on a gelatin hydrogel vehicle prior to performing a pilot
study to evaluate the effects of this cell type on collateral arteriogenesis in a BALB/c hindlimb
ischemic mouse model. Myogenic cell isolation, culture, and characterization were optimized to
ensure a large population of proliferating myoblasts were obtained. These cells were then plated
on a gelatin hydrogel where their phenotype was assessed to develop an effective method of
transplanting them. The final step was to transplant them into the in vivo model and measure their
effect on collateral arteriogenesis. The transplantation of myogenic cells did not enhance
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collateral arteriogenesis. However, the whole process was successful in developing an optimized
methodology to isolate, culture, and assess myogenic cells in culture and on a gelatin hydrogel
vehicle, which resulted in a defined and reliable approach to be implemented in future studies.
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6. APPENDICES
A. Experimental Protocols
Myofiber Isolation
Date: ___
Purpose
To excise whole mouse Extensor Digitorum Longus (EDL) muscles, isolate individual live myofibers from whole muscles,
and plate live myofibers in culture conditions to facilitate the primary culture of myoblasts.
Necessary Material
•
•
•
•
•
•
•
•
•
•
•
•

•
•
•
•
•
•
•
•
•
•
•
•

Wash media (10% FBS in Base Media)
Base media (1% Pen-Strep in HAMs F10)
Growth media (20% FBS in Base Media)
SB 203580 working solution (5 mM)
bFGF working solution (1μg/mL)
Collagenase II solution (2mg/mL)
Horse Serum (HS)
ECM coating solution (1:100)
18 MΩ Water
T 12.5 flask (cell culture treated)
10 cm TC dishes (x5)
15 mL conical tubes

Sterile Filter System
Sterile PBS (1x)
P1000 micropipette aid and tips
P20 micropipette aid and tips
Standard pattern forceps
Curved iris scissors
5/45 Forceps (x2)
Beveled long bore glass pipettes
Cotton swabs
2x2, 4x4 gauze pads
Isopropyl Alcohol (IPA)
Styrofoam working surface

Mouse Information
Age: ___________(3-4 week)
Sex:____________
Weight:_________
Genotype:_______
TC Dish Preparation
1. ___ Coat a T12.5 with 0.5 mL ECM coating
2. ___ Allow final plate to coat overnight on
rocking platform (~ 10 rpm)
3. ___ In the morning wash plate with sterile PBS
a. 10 minutes per wash on rocking
platform (~ 10 rpm)
b. 2 washes
c. Wash with wash media (Sterile filter
media)

e. Aspirate excess HS from TC dishes
3. ___ Place 15 mL of wash media into Dish 1
4. ___ Place 5 mL of wash media into Dishes 2-4
5. ___ Warm plates in 37⁰C, 5% CO2 incubator
Muscle Excision – Extensor Digitorum Longus (EDL)
1. ___ Euthanize mouse
2. ___ Use insulin syringe needles to secure fore
and hind limbs to Styrofoam working surface
3. ___ Thoroughly spray hindlimbs with IPA
4. ___ Carefully remove the skin of both hindlimbs
a. The hindlimb should be exposed from
the knee joint to the midpoint of each
foot
5. ___ Carefully remove connective tissue around
the Tibialis Anterior (TA) Muscle
a. Make sure to expose the origin of the
EDL at the knee
6. ___ Create a pocket deep to the distal TA
tendon below the ankle
7. ___ Cut the distal TA tendon
8. ___ Holding the TA by its distal tendon, pull it
towards the knee cutting away connective
tissue as needed to separate it from the EDL

Collagenase Incubation Solution
1. ___ Weigh out 6 mg of type II collagenase
2. ___ In BSC combine with 3 mL of Base Media
3. ___ Resuspend well
Muscle Fiber Wash Plates
1. ___ Defrost aliquot of HS
2. ___ In BSC, Coat 4x 10cm dishes in HS
a. Label TC dishes 1-4
b. Pipette 7 mL of HS into first 10 cm dish
c. Transfer HS between dishes
d. Place remaining HS in 15 mL conical and
place in 37⁰C water bath
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1. ___ Cut the TA at its origin and set aside to
expose the EDL
2. ___ Create a pocket deep to the distal EDL
tendon
3. ___ Cut the Distal EDL tendon
4. ___ Holding the cut tendon, carefully pull EDL
towards the knee separating it from the
surrounding tissue
a. Avoid stretching the muscle as it will
damage individual myofibers
5. ___ Cut the proximal EDL tendon
a. Tendon to Tendon isolation is critical to
maintain fiber integrity
6. ___ Place EDL muscle into 3.0 mL of collagenase
solution
7. ___ Repeat process for contralateral hindlimb
a. placing muscles in collagenase solution
more than 5 min apart will lead to
uneven digestion

8. ___ Coat glass pipettes in HS
9. ___ Use glass pipettes to remove muscles from
the 15 mL conical and transfer into the first dish
a. Place both muscles into the first dish
b. Place collagenase solution back into the
water bath (in case further digestion is
needed)
10. ___ Use glass pipettes to dissociate muscles
a. Progressively use smaller bevel
pipettes as the muscle becomes more
dissociated
b. The muscle should only be washed with
media or gently pipetted up and down
11. ___ Coat P1000 pipette tips with HS
12. ___ Use a dissecting scope and P1000 pipette to
pick out individual live myofibers from the dish
a. Live myofibers will appear shiny or clear
and be straight or crinkly
b. Dead myofibers will appear opaque and
bent or short
13. ___ Place all live fibers in the next numbered
dish
a. Muscles should not remain out of the
incubator for more than 10 min
14. ___ Repeat transfer process for the other wash
dishes
15. ___ Transfer fibers as described into the ECM
coated dish
16. ___ In a BSC, add 2 μL bFGF solution per 1mL of
media
17. ___ In a BSC, add 2 μL P38 inhibitor solution
(5mM) per 1mL of media
18. ___ Place final dish back in the incubator
a. Myoblasts should begin to migrate from
the myofibers within 3 days
b. Feed after 5 days (Partial media change
performed by transferring old media
into a conical with 5mL of fresh warm
media and transferring 5mL of the
solution into the flask)
19. ___ Passage cells upon local confluence or
average 80% confluence

Muscle Digestion
1. ___Place 15 mL conical with EDL muscles and
collagenase in 37⁰C water bath
2. ___ Repeatedly invert the 15 mL conical for
every 10 min of incubation
3. ___ Incubate for 10 min
a. Digestion can take between 10-30 min
depending upon collagenase activity
4. ___ Following 10 min, remove 15 mL conical
every 5-10 min and inspect for proper digestion
a. Use dissecting microscope light on
brightest setting for lighting
b. When properly digested individual
myofibers should begin to protrude
from the surface of the muscle belly
c. If the muscle appears fuzzy under a
dissecting microscope or individual
fibers appear fat and milky in color, the
muscle has been overdigested
5. ___ Upon proper digestion level, remove 15 mL
conicals with HS and muscles from the water
bath
6. ___ Spray conicals down with IPA
7. ___ Remove dish 1 from incubator

NOTES:
• EDL muscles will have individual fibers protruding from the surface and slightly separate in the body of the muscle
when properly digested
• The use of a wash dish (dish 4) is only necessary if a large number of dead or fragments of fibers are impeding the
aspiration of live fibers only. You only want to aspirate live fibers
• Cells should be passed when large, dense (80% confluent) colonies appear around fibers. If cells start to elongate
(starting to differentiate), they should also be passed
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Primary Myoblast Expansion Protocol
Date:
Purpose: To expand primary mouse myoblasts from live Extensor Digitorum (EDL) muscle fibers
Necessary Materials:
• Growth Media (20% FBS in Base Media)
• SB 203580 working solution (5 mM)
• bFGF working solution (1μg/ml in PBS)
• Cell Dissociation Solution - EDTA (Fisher 13151014)
• PBS (-/-, Ca+2, Mg+2)
• ECM coated flask
• Microvial
• Hemocytometer
1. ___ Obtain an ~80% confluent culture vessel
a. myoblasts will begin to differentiate and form myotubes as they approach confluency
b. Takes up to 8 days before they are ready to pass
2. ___ Clean Phase Contrast Microscope with 70% v/v Isopropanol (IPA)
3. ___ Image save pictures of the culture with a phase contrast microscope
4. ___ Determine passage ratio to be used
a. myoblasts should not be split at a ratio higher than 1:3
EDTA Passaging
1. ___ Warm Growth media and factors in 37C H2O bath immediately before use
2. ___ Aspirate media from culture vessel
3. ___ Wash with DPBS (-/-) and aspirate (repeat 2x)
4. ___ Add warm Cell Dissociation solution
a. 0.066 ml/cm2 surface (T12.5 – 0.8 ml, T75 – 5 ml)
5. ___ Immediately place in incubator for ~5 min
6. ___ Observe with phase contrast microscope
a. cells should begin to ball up and become phase bright
7. ___ Hit the flask repeatedly to dislodge weakly adherent cells
a. more differentiated cells will more strongly adhere to the dish
8. ___ If insufficient cells have detached, return to the incubator for an additional min
9. ___ Repeat process until sufficient cells have detached
a. highly differentiated cells may never detach
b. cells can be selectively passaged by altering incubation time/hitting of the flask
10. ___ Add the same volume of Growth Media as EDTA to prevent further chelation
11. ___ Label a 15 ml conical tube and transfer the cell suspension
12. ___ Count cells using hemocytometer
13. ___ Centrifuge at 300g for 5 min to create a cell pellet
14. ___ Aspirate media from the conical
a. be careful to avoid aspirating the pellet
15. ___ Resuspend in the volume of growth media (+ factors) appropriate for the chosen passage ratio
16. ___ Repeatedly pipette up and down to break of cell clumps
17. ___ Rock the culture vessel repeatedly: forward/back and left/right to evenly disperse the cells
a. Even cell distribution can be checked under the phase contrast microscope
18. ___ Place in incubator
a. close the door gently to prevent uneven cell distribution
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Myoblast Antibody Staining
Date:
Purpose:
To fix and stain myoblasts using antibody stains in order to assess their phenotype
Necessary Materials
• 8 Well Chamber Slide
• ECM Coating
• 4% Paraformaldehyde
• PBS
• Aluminum Foil

•
•
•
•

UltraCruz Blocking Reagent
Triton X-100
Primary Conjugated Antibodies
Mounting Medium (W/ DAPI)

Slide prep, fixation, and solution prep
1. ___ In a Biological Safety Cabinet (BSC) coat 8 Well Chamber Slide with ECM coating
a. 0.2 mL per well
b. Coat on rocking platform (10 rpm) for either:
i. 3 hours at RT
ii. overnight at RT
2. ___ Aspirate Coating
3. ___ Wash twice in PBS for 10 min
4. ___ Add 6x104 cells per well diluted in 0.5 mL of media
5. ___ Incubate until cells adhere (12-24 hours)
6. ___ Aspirate media and fix in 4% Paraformaldehyde at room temperature for 10 minutes (enough to cover surface)
7. ___ Aspirate PBS and wash twice in PBS and store in PBS (0.2 mL)
a. Fixed cells can be stored prior to staining for up to 10 days
8. ___ Prepare permeabilization solution: 0.5% Triton X-100 in PBS
9. ___ Primary Conjugated Antibodies (1:200 MyoD, 1:100 PAX7) diluted in UltraCruz Blocking reagent
Staining
1. ___ Wash three times in PBS
2. ___ Aspirate PBS and add permeabilization solution for 5 minutes
3. ___ Aspirate permeabilization solution and add blocking solution for 30 minutes
4. ___ Wash in PBS for 5 minutes
5. ___ Incubate primary conjugated antibody solution at room temperature in the dark for 60 minutes
6. ___ Aspirate primary conjugated antibody solution wash three times in PBS for 5 minutes each
7. ___ Mount coverslip with mounting medium containing DAPI
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Sterile Gelatin Preparation
Date:________________
Sterile Materials
• 25ml Erlenmeyer flask
• Rubber stopper + tubing
• Rubber stopper
• Spatula
• Distilled H2O
• Gelatin powder

•
•
•
•
•

10mL syringe
Syringe filter
Pipettes
50 mL conicals
24 Well Plate

Non-Sterile Materials
• Hot plate
• Analytical balance
• 6mM EDC in DI-water
Procedure
1. ___Turn hot plate on to 200C.
2. ___In laminar flow hood, open sterile packs
with Erlenmeyer flask and rubber stopper.
3. ___Weigh empty 25ml Erlenmeyer flask +
rubber stopper on an analytical balance and
zero the balance.
4. ___Bring the Erlenmeyer flask back to the
hood along with the gelatin.
5. ___Open the sterile pack with the spatula
and use it to put some gelatin powder into
the Erlenmeyer flask.
6. ___Put the rubber stopper back on the flask
and weigh it on the analytical balance.
7. ___Add enough distilled H2O to the flask to
make a 10% gelatin solution (by weight).
8. ___Open the sterile pack with the rubber
stopper + tubing and put it on the flask.

9. ___Place flask on the hot plate, wait to boil,
and then allow it to boil for 5 minutes.
10. ___In the hood, put 0.25mL of the gelatin
solution in each well of a 24 well plate.
11. ___While the gelatin in solidifying, use the
syringe filters to filter the 6mM EDC.
12. ___Once the gelatin has solidified, add
0.5mL of EDC to each well.
13. ___Leave the gelatin in the EDC solution 48
hours at 4C to allow for crosslinking.
14. ___The next day aspirate the EDC solution
and wash the gel 3x30 minutes with sterile
H2O.
15. ___ Seed each well of with 0.5 mil Myoblast
suspended in 1mL of wash media.

Note: The measurements and seeding densities are given for 24 well plate. They need be
adjusted if different size well is used.
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Date_________

Functional Vasodilation with Trans-illumination Surgical Exposure

Purpose: To quantify the functionality of the gracilis

__28.

collateral by measuring vessel dilation before and after
electronically stimulating the muscle. It is important to
quantify the response to increased metabolic demand because
it provides a functional endpoint for assessing arteriogenesis.

__29.

Safety Considerations
o
o

Avoid contact with the electrode during stimulation
to avoid shock
Handle surgical instruments delicately/with caution
to avoid puncturing oneself or others

__30.
__31.
__32.

Materials
__1.
Standard pattern forceps (1)
__2.
Fine forceps- S&T (2)
__3.
Sharp forceps- 5/45 (1)
__4.
Curved iris scissors (1)
__5.
Retractors (2)
__6.
Depilatory cream- Veet
__7.
Cotton Swabs
__8.
Gauze Sponges (2x2 and 4x4)
__9.
Lubricant for temperature probe
__10. Surgical tape
__11. Heat pad w/ rectal probe
__12. 10mL syringe (PBS sterilization)
__13. Syringe filter (PBS ster.)
__14. Saline (PBS)
__15. Tungsten microelectrodes (2xwidth)
__16. Clay
__17. Plastic wrap
__18. Stage w/ attached Cyan Trans-illuminators
__19. Intravital microscope- Olympus BXFM
__20. Digital imaging software- QCapturePro
__21. 10^ -[4-5] sodium nitroprusside (SNP) at
37C (keep protected from light while thawing)
__22. 10^ -[4-5] norepinephrine (NE)
__23. 70% isopropyl alcohol (IPA)

__33.
__34.

Initials________

Apply a thick coating of depilatory cream to
hindlimb with a cotton swab. Let sit for 1-3
minutes.
Drywipe with enough force to remove the hair
and cream w/o irritating the skin. Wet a 2x2
gauze sponge with PBS and wipe hindlimb clean
of cream and hair
Flip animal over and use clippers to shave
hair from the posterior side of the hindlimbs
Complete hair removal w/ depilatory cream
Cover heat pad w/ 4x4 gauze sponge and
transfer animal to surgery stage
Apply lubricant to rectal probe and insert. Set
thermo-controller to 35C
Tape hindlimb flat, as perfectly horizontal in
same plane as stage, as possible over LED

Surgical Exposure
__35. Make a small incision on the middle, medial
aspect of the left hindlimb
__36. Continue to make a circular incision from the
saphenous to the epigastric fat pad
__37. Remove just enough skin to create “a bowl” for
the PBS
__38. Blunt dissect and remove the connective tissue
overlying the gricilis muscle
__39. Remove the construct from the pocket deep to
the gracilis muscle. Place construct in PBS.
__40. Remove skin from the back of hindlimb and
cover with plastic wrap? (if necessary)
__41. Set frequency to 1 Hz (1000ms pulse interval),
the duration to 200μs, and the current to 1 mA
__42. Set up microelectrodes to isolated stimulator
__43. Use clay to hold leads at the base of the
electrodes in place
__44. Position the electrodes w/ the tips resting on the
surface of the gracilis anterior midway between
the saphenous and profunda
__45. Turn on the stimulator and start stimulation
__46. Adjust electrode placement and current for a
maximal localized contraction, then stop
stimulation
__47. Apply PBS to tissue, cover preparation with
plastic wrap for entire duration, and equilibrate
for 30 minutes to regain resting vascular tone

Animal Preparation
__24. Place animal in induction chamber
__25. Open oxygen cylinder. Set flow high and
isofluorane to 5%
__26. Once anesthetized, weigh animal and move
to preparatory bench in a supine position
__27. Reduce isofluorane to 1-3% and flow to 0.51.5 l*min^-1
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__48.

Repeat the surgical exposure, equilibrate,
complete electrode test and FVD procedures on
control limb

Functional Vasodilation
__49. Change the frequency to 8 Hz (125 ms pulse
interval)
__50. Switch on the trans-illuminator and place clay to
block light from eyes
__51. Open QCapturePro and position the intravital
microscope above the collateral arteriole
__52. Acquire resting images of the arteriole in the
Midzone (if possible: Reentry and Stem)
__53. Stimulate the muscle for 90 seconds
__54. Capture images of collateral immediately after
simulation (series of 10), save all images
acquired (if possible: reentry, stem)
__55. Remove plastic wrap and maximally dilate by
applying SNP, cover with plastic wrap again
__56. Capture images at point of maximum dilation
(max wait time is 5 minutes), save all images
acquired (if possible: reentry, stem)
__57. Remove plastic wrap and rinse muscle with PBS
__58. Maximally constrict with NE, cover with plastic
wrap again
__59. Capture images at point of maximum
constriction (max wait time is 5 minutes), save
all images acquired (if possible: reentry, stem)
Post-Surgical
__60. Blunt dissect gracilis anterior to be able to resect
__61. Pass to perfusion fixer or perform cervical
dislocation to euthanize animal
__62. Turn off isofluorane, flow, and close oxygen
__63. Wash all instruments used during procedure
__64. Wipe down the surgical area with IPA
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Initials ______________
Perfusion Fixation, Microfil Vascular Casting, and Dissection Protocol
Date ______________________
Mouse Information
DOB: ____________________________
Sex: _____________________________
Genotype/strain: ___________________
Cage: ____________________________
Weight (g): ________________________
Materials
Non-Sterile Instruments
___ 1. Standard Pattern Forceps (1)
___ 2. Bone Scissors (1)
___ 3. Iris Scissors (1)
___ 4. Hemostats (1)
___ 5. Microdissection Scissors (1)
___ 6. Vascular Clamp (1)
Obtained in surgery site
___ 7. Tape
___ 8. 20 mL Syringe (1)
___ 9. 10 mL Syringes (2)
___ 10. Bench cover
___ 11. Heating pad
___ 12. Catheter with PE-100 tubing
___ 13. Tubing with stopcock
___ 14. Isoflurane Anesthetic
___ 15. 2x2 & 4x4 Gauze sponges
___ 16. Silk suture
___ 17. Syringe pump
Vasodilator Cocktail Preparation
___ 18. Turn on water bath to 37°C
___ 19. 400 µL Heparin
___ 20. 1 mL Sodium Nitroprusside (SNP) (orange)
___ 21. 600 µL Adenosine (clear)
___ 22. 38 mL PBS solution
___ 23. Thaw SNP and Adenosine
___ 24. Add heparin, SNP, Adenosine, and PBS
solution in a 50 mL conical
___ 25. Place vasodilator cocktail in water bath
Microfil Cocktail Preparation
___ 26. 2 mL Microfil MV-120
___ 27. 1.5 mL Microfil HV-Diluent
___ 28. 1.25 mL Microfil MV-Diluent
___ 29. Add MV-122, HV-Diluent, and MV-Diluent
into a 15 mL conical, vortex, and place in bath

Procedure Preparation
___ 30. Weigh animal
___ 31. Obtain saline filled petri-dish, cotton swab,
and instruments
Fixation
___ 32. If not already anesthetized, anesthetize
mouse with Isoflurane
___ 33. Tape all 4 limbs to a gauze sponge over the
heating pad in the supine position such that its
nose is in the nose cone
___ 34. Insert rectal temperature probe and turn
on heating pad
___ 35. Loosely tie a tourniquet around both
ankles
___ 36. Fill the 20 mL syringe with 20mL of the
vasodilator cocktail, attach the tubing with a
stopcock, and place in the syringe pump
___ 37. Using standard pattern forceps and iris
scissors, tent the skin below the sternum and cut
laterally
___ 38. Cut both sides of the skin up to the clavicle
such that the incision is in a U shape
___ 39. Blunt dissect the connective tissue away
between the skin and ribcage
___ 40. Using bone scissors and forceps, cut the
ribcage up to the clavicle, cut laterally across the
diaphragm, and cut the other side of the ribcage
up to the clavicle
___ 41. Clamp the ribcage at the sternum with the
hemostats and reflect it over the head
___ 42. Tear connective tissue around the heart,
insert needle into the apex of the heart, and cut
the right atrium
___ 43. Inject vasodilator cocktail at 5mL/min with
syringe pump until the saphenous vein clears and
soak excess blood with 4x4 gauze
___ 44. Inject 5mL of 4% PFA at 4mL/min
___ 45. Add 0.2 mL of curing agent to Microfil
cocktail
___ 46. Draw up Microfil cocktail in 10 mL syringe
and attach the catheter and tubing
___ 47. Make a small incision in the apex of the
heart, insert catheter, and clamp with vascular
clamp
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___ 48. Inject 2 mL of Microfil cocktail at
0.5mL/min
___ 49. Once Microfil has passed the knee, pause
the Microfil and tie the tourniquets around both
ankles tightly. Resume Microfil until satisfied
___ 50. After letting the mouse sit for 5 minutes,
remove mouse from heat pad and take out
catheter while leaving vascular clamp
___ 51. Place mouse in bag (cover open wounds
with saran wrap) and let sit overnight in fridge
___ 52. Cover scope, turn off water bath, turn off
oxygen and Isoflurane, clean instruments
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B. Statistical Analysis
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C. Supplemental Figures

Figure S1: Myofiber Isolation Process. A, Myofibers begin to protrude out of muscle
body following enzymatic digestion. B, Viable (green arrow) and hypercontracted (red
arrow) myofibers. C, Mechanical separation of myofibers from muscle body. D,
Myofibers prior to separation and introduction into culture flask.
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Figure S2: Sample Control Stain. A, B, Myoblasts labeled using DAPI
nuclear stain (A) and Pax7 (B). C, D, Fibroblasts (NIH-3T3) labeled using
DAPI nuclear stain (A) and Pax7 (B). Fibroblasts stained negative for Pax7,
confirming the selectivity of the antibody and validity of the
immunostaining protocol. E, F Myoblasts cultured on gelatin labeled using
DAPI nuclear stain (E) and Pax7 (F). G, H, Fibroblasts cultured on gelatin
(NIH-3T3) labeled using DAPI nuclear stain (G) and Pax7 (H). Fibroblasts
stained negative for Pax7, confirming the selectivity of the antibody (Scale
bars: 20µm)
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Figure S3: Common Morphology of Myogenic Cells During Troubleshooting. A, B, Day 3
(A) and day 7 (B) myoblasts in culture without (or expired) bFGF supplementation. C, D, Day
3 (C) and day 7 (D) myoblasts in culture without SB 203580 supplementation. E, F, Day 3 (E)
and day 7 (F) myoblasts in culture supplemented with expired (defective) SB 203580.
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